Fortrea Holdings (FTRE) Other Non-Current Assets (2022 - 2026)
Fortrea Holdings (FTRE) reported Other Non-Current Assets of $86.1 million for Q1 2026, down 15.09% on a YoY basis from $101.4 million in Q1 2025, and up 6.56% quarter-over-quarter from $80.8 million in Q4 2025.
Fortrea Holdings (FTRE) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Other Non-Current Assets for 5 years, with the latest figure at $86.1 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 15.09% year-over-year to $86.1 million; the trailing twelve-month figure through Mar 2026 stood at $86.1 million (down 15.09% YoY), and the FY2025 full-year result was $80.8 million, down 21.86% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $86.1 million, up from $80.8 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $103.4 million in Q4 2024, with the low at $54.3 million in Q4 2022.
- Historically, Other Non-Current Assets has averaged $81.8 million across 5 years, with a median of $80.8 million in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets soared 48.35% — and 2025, when it fell 21.86%.
- Fortrea Holdings' Other Non-Current Assets stood at $54.3 million in 2022, then rose by 28.36% to $69.7 million in 2023, then soared by 48.35% to $103.4 million in 2024, then slipped by 21.86% to $80.8 million in 2025, then climbed by 6.56% to $86.1 million in 2026.
- The last three Other Non-Current Assets figures came in at $86.1 million (Q1 2026), $80.8 million (Q4 2025), and $74.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 86.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.10 Mn |
| Dec 31, 2025 | 80.80 Mn |
| Sep 30, 2025 | 74.20 Mn |
| Jun 30, 2025 | 101.30 Mn |
| Mar 31, 2025 | 101.40 Mn |
| Dec 31, 2024 | 103.40 Mn |
| Mar 31, 2024 | 74.90 Mn |
| Dec 31, 2023 | 69.70 Mn |
| Sep 30, 2023 | 69.70 Mn |
| Jun 30, 2023 | 83.70 Mn |
| Dec 31, 2022 | 54.30 Mn |